Gesundheitsreform: Die Pharmaindustrie und der Streit ums Sparen

The article discusses the tension between Germany's health reform and the pharmaceutical industry's competitiveness, focusing on Sanofi's Heidrun Irschik-Hadjieff's warnings about the impact of a proposed dynamic manufacturer discount on future investments. It also touches on digital sovereignty debates in Europe and the role of the 'Power & Policy' podcast in analyzing economic policy decisions.